| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Thomas King | |
| Zhimin Guo | |||
| P2860 | cites work | High affinity of copper(II) towards amoxicillin, apramycin and ristomycin. Effect of these complexes on the catalytic activity of HDV ribozyme. | Q46126816 |
| Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon | Q46727946 | ||
| Safety and efficacy of RNAi therapy for transthyretin amyloidosis | Q46836193 | ||
| Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. | Q50575493 | ||
| Hepatitis delta virus | Q54152890 | ||
| Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023. | Q54478541 | ||
| Efficacy of peginterferon alpha-2b in chronic hepatitis delta: Relevance of quantitative RT-PCR for follow-up | Q57782781 | ||
| Overexpression of clusterin in human hepatocellular carcinoma | Q81314820 | ||
| The large form of ADAR 1 is responsible for enhanced hepatitis delta virus RNA editing in interferon-alpha-stimulated host cells | Q24304329 | ||
| Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression | Q24522443 | ||
| RNA-templated replication of hepatitis delta virus: genomic and antigenomic RNAs associate with different nuclear bodies | Q24548934 | ||
| A single antigenomic open reading frame of the hepatitis delta virus encodes the epitope(s) of both hepatitis delta antigen polypeptides p24 delta and p27 delta | Q24646279 | ||
| Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep) | Q24670052 | ||
| Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery | Q26849602 | ||
| Structural basis of the oligomerization of hepatitis delta antigen | Q27764886 | ||
| Liver Disintegration in the Mouse Embryo Caused by Deficiency in the RNA-editing Enzyme ADAR1 | Q28184194 | ||
| Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures | Q29615028 | ||
| Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis | Q33404425 | ||
| Modification of small hepatitis delta virus antigen by SUMO protein | Q33558331 | ||
| Phosphorylation of serine 177 of the small hepatitis delta antigen regulates viral antigenomic RNA replication by interacting with the processive RNA polymerase II. | Q33614472 | ||
| Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users | Q33654601 | ||
| Increasing incidence of recent hepatitis D virus infection in HIV-infected patients in an area hyperendemic for hepatitis B virus infection. | Q33813200 | ||
| Long-term therapy of chronic delta hepatitis with peginterferon alfa. | Q33904679 | ||
| Assembly of hepatitis delta virus particles | Q33932270 | ||
| A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance | Q33933196 | ||
| Hepatitis D virus: an update | Q34024141 | ||
| Varied immunity generated in mice by DNA vaccines with large and small hepatitis delta antigens. | Q34227136 | ||
| Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses. | Q34457758 | ||
| Catalytic strategies of the hepatitis delta virus ribozymes | Q34667466 | ||
| Combination of DNA prime--adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model | Q34778476 | ||
| The hepatitis delta virus RNA genome interacts with the human RNA polymerases I and III. | Q34952799 | ||
| Hepatitis delta virus epigenetically enhances clusterin expression via histone acetylation in human hepatocellular carcinoma cells | Q34957522 | ||
| Viral hepatitis: past and future of HBV and HDV. | Q35045045 | ||
| Pegylated Interferon α Therapy in Chronic Delta Hepatitis: A One-Center Experience | Q35267105 | ||
| Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate Co-transporting Polypeptide | Q35526264 | ||
| Assembly of hepatitis delta virus: particle characterization, including the ability to infect primary human hepatocytes | Q35785074 | ||
| Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. | Q36428213 | ||
| Identification of an intrahepatic transcriptional signature associated with self-limiting infection in the woodchuck model of hepatitis B. | Q36476515 | ||
| Breaking the central dogma by RNA editing | Q36559666 | ||
| Isoprenylation masks a conformational epitope and enhances trans-dominant inhibitory function of the large hepatitis delta antigen | Q36633321 | ||
| Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection | Q36883851 | ||
| Prime/boost immunization with DNA and adenoviral vectors protects from hepatitis D virus (HDV) infection after simultaneous infection with HDV and woodchuck hepatitis virus. | Q36978876 | ||
| The large form of hepatitis delta antigen is crucial for assembly of hepatitis delta virus | Q37597959 | ||
| Virology of hepatitis D virus | Q38039005 | ||
| Treatment of chronic delta hepatitis | Q38039010 | ||
| Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. | Q38046628 | ||
| Life cycle and pathogenesis of hepatitis D virus: A review | Q38177275 | ||
| Mouse models of hepatitis B and delta virus infection | Q38196163 | ||
| Strategies to inhibit entry of HBV and HDV into hepatocytes. | Q38207387 | ||
| Current status in the therapy of liver diseases | Q38208508 | ||
| Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides | Q38301148 | ||
| Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. | Q38310253 | ||
| Proteomic changes in HEK-293 cells induced by hepatitis delta virus replication. | Q39139176 | ||
| Large hepatitis delta antigen activates STAT-3 and NF-κB via oxidative stress | Q39281231 | ||
| Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo | Q39368000 | ||
| Treatment options for hepatitis delta virus infection | Q39502937 | ||
| In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. | Q39793276 | ||
| Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans | Q39823787 | ||
| Intracellular localization of hepatitis delta virus proteins in the presence and absence of viral RNA accumulation. | Q39860676 | ||
| Hepatitis delta virus inhibits alpha interferon signaling | Q39904698 | ||
| Induction of cytotoxic T lymphocyte responses against hepatitis delta virus antigens which protect against tumor formation in mice | Q40778961 | ||
| Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection | Q41399410 | ||
| Design of potential siRNA molecules for hepatitis delta virus gene silencing | Q41841424 | ||
| Viral hepatitis. HBV cure--can we pin our hopes on immunotherapy? | Q42174019 | ||
| Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study | Q42204820 | ||
| Resolution of chronic hepatitis Delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine | Q43242166 | ||
| Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study | Q44830085 | ||
| A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice | Q45353109 | ||
| The increasing prevalence of hepatitis delta virus (HDV) infection in South London | Q45398479 | ||
| An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. | Q45874701 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virus | Q808 |
| catalysis | Q82264 | ||
| organic chemistry | Q11351 | ||
| hepatitis delta virus | Q1607636 | ||
| host microbial interaction | Q68260314 | ||
| RNA virus infectious disease | Q18967413 | ||
| antiviral agent | Q40207875 | ||
| P304 | page(s) | 19537-52 | |
| P577 | publication date | 2015-08-18 | |
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | Therapeutic Strategies and New Intervention Points in Chronic Hepatitis Delta Virus Infection | |
| P478 | volume | 16 |
Search more.